News Headlines Article

Gilead teams with startup to turn machine learning on fatty liver disease
San Francisco Business Times

Even before much of the world last year found out about Daphne Koller’s machine-learning-driven drug development company, she was invited to speak to Gilead Sciences Inc. scientists. The ensuing conversations have led Koller’s Insitro to formally work with Gilead to find new targets for drugs to attack one of the hottest areas in drug development.

The companies disclosed the three-year deal Tuesday morning. Insitro will receive $15 million upfront, plus “near-term” milestone payments up to $35 million and as much as $200 million for hitting preclinical, development, regulatory and commercial milestones for each of five Gilead targets in the fatty liver disease known as nonalcoholic steatohepatitis, or NASH.